Quality of Life After Radical Prostatectomy
|
|
|
- Trevor Parks
- 9 years ago
- Views:
Transcription
1 Quality of Life After Radical Prostatectomy Bernard H. Bochner, MD FACS Attending Surgeon, Urology Service Vice Chairman, Department of Surgery Memorial Sloan-Kettering Cancer Center
2 Quality of Life After Radical Prostatectomy Individual series data available HOWEVER: Poor characterization of patient groups (case mix) Variation in reporting method Different definitions for outcomes The lack of high quality evidence makes comparative evaluations between different treatments difficult No QOL data from randomized trials available
3 Health-Related Quality of Life Patient-centered variable taken from the field of health services research Can be measured reliably Questionnaires (instruments) are pilot-tested the validated Domains can be general or disease-specific Responses to items are scored and can be used to calculate a summary score for each domain
4 Patients; N=1201; Spouses, N=625 Treatment Modalities Radical Prostatectomy, N=603 Brachytherapy, N=306 External Beam Radiotherapy, N=292
5 Sexual function caused moderate or severe distress after 2 years: in 43% of men after RP, 37% after XRT and 30% after brachy; ED caused distress in 44%, 22% and 13% of partners. Urinary function lead to moderate or severe distress after 1 yr: in 7% of patients after RP, 18% after brachy, and 11% after XRT, and in 4-5% of partners. GI symptoms caused moderate or severe distress in 9% of patients (and 4-5% of partners) a year after radiation (brachy or XRT).
6 Figure 1. Changes in Quality of Life after Primary Treatment for Prostate Cancer.
7 Surgeon Factor: Outcomes after Radical Prostatectomy To what degree are the outcomes of radical prostatectomy perioperative complications, urinary incontinence, erectile dysfunction, surgical margins and long term cancer control related to surgical technique in addition to the characteristics of the patient and the cancer?
8 Variability in 5-yr progression-free probabilities among experienced surgeons (>40 cases) adjusted for case mix p<0.0005
9 Heterogeneity in outcome among surgeons at MSKCC: full continence (no pads) Bianco et al J Urol 2010
10 Heterogeneity in outcome among surgeons at MSKCC: full potency (+/- oral agents) Bianco et al J Urol 2010
11 Effect of Surgeon and Hospital Volumes For Radical Cystectomy Adjusted Mortality operative mortality is largely mediated by surgeon volume. Patients can often improve their chances of survival substantially by selecting surgeons who perform the operation frequently. Birkmeyer et al, NEJM, 2003
12 Surgeon and Impact On Outcome After RRP: High Volume Surgeons Outcomes (%) Low Medium High Very high Surgeon Volume 0 Postoperative complications Late urinary complications Long-term incontinence Begg CB, Reidel ER, Bach PB, Kattan MW, Schrag D, WarrenJL, Scardino PT. Variations in morbidity after radical prostatectomy. NEJM 2002; 346:1142.
13 Surgeon and Impact On Outcome After RRP: Urinary Complications, High Volume Surgeons Expected (n=159) > 50 % Late Urinary Complications after RP (Bianco F et al. J Urol 2005)
14 Surgeon and Impact On Outcome After RRP: Urinary Complications, High Volume Surgeons Expected Observed p <.0001 % Late Urinary Complications after RP > 50
15 Achieving Optimal Outcomes after Radical Prostatectomy: The Trifecta Optimal outcome after RP is cancer control with full recovery of continence and potency. Individual studies report rates of ED, incontinence or cancer recurrence (rising PSA) in isolation. These rates do not adequately reflect the quality of the surgery nor fully inform patients of the probability of being cured of cancer and recovering normal urinary and sexual function ( Trifecta ). Saranchuk J, J Clin Oncol 2005; 23:4146
16 Cummulative Incidence Probabilities of Event Probability of recovering complete continence, normal erectile function and freedom from biochemical recurrence ( Trifecta ) after RP alone Trifecta Outcomes (Potent, Continent, PSA undetectable) Failure of RP to control prostate cancer N=647 Markov model Time (Months) from Radical Prostatectomy Cumulative probability of continence, potency and freedom from biochemical recurrence Probability of PSA recurrence
17 Variation among surgeons in achieving optimal results (TRIFECTA) Probability of being both potent and continent at 12 months
18 Cumulative Incidence of Recovery of Continence (No Pads or Leakage): Open vs. Lap RP Touijer A et al. J Urol 2008; 197:1811 Open Lap HR 0.56, p<.0005
19 QOL After Radical Prostatectomy Conclusion All treatments for prostate cancer adversely effect QOL Poor quality comparative data makes direct comparisons very difficult Surgical skill strongly associated with oncologic and functional outcomes after RRP Technology has not proven to provide major breakthrough in improved QOL over good open surgery.
Prostatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.
Adjuvante und Salvage Radiotherapie Ludwig Plasswilm Klinik für Radio-Onkologie, KSSG CANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTS 1983 1998 Clinical stage T1 and T2 Mean
Beyond the PSA: Genomic Testing in Localized Prostate Cancer
Beyond the PSA: Genomic Testing in Localized Prostate Cancer Kelvin A. Moses, MD, PhD Vanderbilt University Medical Center Wednesday, December 2, 2015 5:00 p.m. ET/2:00 p.m. PT About ZERO ZERO s mission
7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
Thomas A. Kollmorgen, M.D. Oregon Urology Institute
Thomas A. Kollmorgen, M.D. Oregon Urology Institute None 240,000 new diagnosis per year, and an estimated 28,100 deaths (2012) 2 nd leading cause of death from cancer in U.S.A. Approximately 1 in 6 men
Prostate Cancer Treatment Comparison
Prostate Cancer Treatment Comparison Treatment Comparative Data Outcome Comparison: Surgery vs. Radiotherapy Outcome Radical Prostatectomy* Radiation** Survival duration compared to conservative disease
Prostate Cancer Treatment Comparison
Prostate Cancer Treatment Comparison Treatment Comparative Data Outcome Comparison: Surgery vs. Radiotherapy Outcome Radical Prostatectomy* Radiation** Survival duration compared to conservative disease
SRO Tutorial: Prostate Cancer Treatment Options
SRO Tutorial: Prostate Cancer Treatment Options May 7th, 2010 Daniel M. Aebersold Klinik und Poliklinik für Radio-Onkologie Universität Bern, Inselspital Is cure necessary in those in whom it may be possible,
Individual Prediction
Individual Prediction Michael W. Kattan, Ph.D. Professor of Medicine, Epidemiology and Biostatistics, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Chairman, Department
Radiation Therapy for Prostate Cancer: Treatment options and future directions
Radiation Therapy for Prostate Cancer: Treatment options and future directions David Weksberg, M.D., Ph.D. PinnacleHealth Cancer Institute September 12, 2015 Radiation Therapy for Prostate Cancer: Treatment
The Business of Prostate Cancer Care: A Clinician-Researcher s Perspective
The Business of Prostate Cancer Care: A Clinician-Researcher s Perspective David F. Penson, MD, MPH Departments of Urology and Preventive Medicine Keck School of Medicine University of Southern California
Does my patient need more therapy after prostate cancer surgery?
Does my patient need more therapy after prostate cancer surgery? Contact the GenomeDx Patient Care Team at: 1.888.792.1601 (toll-free) or e-mail: [email protected] Prostate Cancer Classifier
Cancer research in the Midland Region the prostate and bowel cancer projects
Cancer research in the Midland Region the prostate and bowel cancer projects Ross Lawrenson Waikato Clinical School University of Auckland MoH/HRC Cancer Research agenda Lung cancer Palliative care Prostate
PSA Screening for Prostate Cancer Information for Care Providers
All men should know they are having a PSA test and be informed of the implications prior to testing. This booklet was created to help primary care providers offer men information about the risks and benefits
NERVE GRAFT TO RESTORE ERECTILE FUNCTION DURING RADICAL PROSTATECTOMY
CLINICAL POLICY NERVE GRAFT TO RESTORE ERECTILE FUNCTION DURING RADICAL PROSTATECTOMY Policy Number: SURGERY 043.13 T Effective Date: October 1, 015 Table of Contents BENEFIT CONSIDERATIONS. APPLICABLE
Questions to ask my doctor: About prostate cancer
Questions to ask my doctor: About prostate cancer Being diagnosed with prostate cancer can be scary and stressful. You probably have a lot of questions and concerns. Learning about the disease, how it
Questions to Ask My Doctor About Prostate Cancer
Questions to Ask My Doctor Being told you have prostate cancer can be scary and stressful. You probably have a lot of questions and concerns. Learning about the disease, how it s treated, and how this
Prostate cancer. Christopher Eden. The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing.
Prostate cancer Christopher Eden The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing. Screening Screening men for PCa (prostate cancer) using PSA (Prostate Specific Antigen blood
Focal therapy for prostate cancer: seriously or seriously? Disclosures
Focal therapy for prostate cancer: seriously or seriously? Mitchell Kamrava, MD Assistant Clinical Professor Department of Radiation Oncology University of California Los Angeles Disclosures Speaking honorarium
Historical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
Local Salvage Therapies After Failed Radiation for Prostate Cancer. Biochemical Failure after Radiation
Local Salvage Therapies After Failed Radiation for Prostate Cancer James Eastham, MD Memorial Sloan-Kettering Cancer Center New York, New York Biochemical Failure after Radiation ASTRO criteria 3 consecutive
Proton Therapy for Prostate Cancer: Your Questions, Our Answers.
Proton Therapy for Prostate Cancer: Your Questions, Our Answers. When you re looking for the right treatment for your prostate cancer, nothing s more important than accurate information. Read on, and learn
Prostate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40.
A.D.A.M. Medical Encyclopedia. Prostate cancer Cancer - prostate; Biopsy - prostate; Prostate biopsy; Gleason score Last reviewed: October 2, 2013. Prostate cancer is cancer that starts in the prostate
Facing Prostate Cancer Surgery? Learn about minimally invasive da Vinci Surgery
Facing Prostate Cancer Surgery? Learn about minimally invasive da Vinci Surgery The Condition: Prostate Cancer Your prostate is a walnut-sized gland that is part of the male reproductive system. The prostate
Precise, Minimally Invasive Prostate Cancer Removal
Precise, Minimally Invasive Prostate Cancer Removal Learn why da Vinci Surgery may be your best treatment option 1 Beyond Minimally Invasive For Prostate Cancer 1 Facing Prostate Cancer Prostate cancer
Screening for Prostate Cancer
Screening for Prostate Cancer It is now clear that screening for Prostate Cancer discovers the disease at an earlier and more curable stage. It is not yet clear whether this translates into reduced mortality
Prostate Cancer Screening: Are We There Yet? March 2010 Andrew M.D. Wolf, MD University of Virginia School of Medicine
Prostate Cancer Screening: Are We There Yet? March 2010 Andrew M.D. Wolf, MD University of Virginia School of Medicine Case #1 A 55 yo white man with well-controlled hypertension presents for his annual
PROSTATE CANCER. Get the facts, know your options. Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology
PROSTATE CANCER Get the facts, know your options Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology i What is the Prostate? Unfortunately, you have prostate
TO SCREEN OR NOT TO SCREEN: THE PROSTATE CANCER
TO SCREEN OR NOT TO SCREEN: THE PROSTATE CANCER DILEMMA Thomas J Stormont MD January 2012 http://www.youtube.com/watch?v=8jd 7bAHVp0A&feature=related related INTRODUCTION A government health panel (the
An Introduction to PROSTATE CANCER
An Introduction to PROSTATE CANCER Being diagnosed with prostate cancer can be a life-altering experience. It requires making some very difficult decisions about treatments that can affect not only the
855-DRSAMADI or 212-241-8779
SMART SURGERY NEWS MARCH 2013 Dr. David Samadi 855-DRSAMADI or 212-241-8779 YOUR PROSTATE CANCER NEWS PREVENTION DIAGNOSIS TREATMENT LIFE AFTER PROSTATE CANCER PREVENTION Prostate Cancer Need-to-Knows
SIOG Guidelines Update 2014 Prostate Cancer. Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon
SIOG Guidelines Update 2014 Prostate Cancer Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, Dickinson L, Efstathiou
The 4Kscore blood test for risk of aggressive prostate cancer
The 4Kscore blood test for risk of aggressive prostate cancer Prostate cancer tests When to use the 4Kscore Test? Screening Prior to 1 st biopsy Prior to negative previous biopsy Prognosis in Gleason 6
Robotic Assisted Laparoscopic Salvage Prostatectomy for Radiation Resistant Prostate Cancer
Robotic Assisted Laparoscopic Salvage Prostatectomy for Radiation Resistant Prostate Cancer Jonathan A. Eandi,* Brian A. Link, Rebecca A. Nelson, David Y. Josephson, Clayton Lau, Mark H. Kawachi and Timothy
Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC)
Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC) FDA Presentation ODAC Meeting September 14, 2011 1 Review Team Paul G. Kluetz,
Survivorship Care Plans Guides for Living After Cancer Treatment
Survivorship Care Plans Guides for Living After Cancer Treatment Institute of Medicine Report 2005 Recommendations for meeting needs of cancer survivors Implement survivorship care plan Build bridges
Carcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology
Carcinoma of the Cervix Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Cervical Cancer Treatment Treatment Microinvasive (Stage IA1): Simple (extrafascial) hysterectomy/cone
These rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.
Prostate Cancer OVERVIEW Prostate cancer is the second most common cancer diagnosed among American men, accounting for nearly 200,000 new cancer cases in the United States each year. Greater than 65% of
Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward
Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward 33 rd Annual Internal Medicine Update December 5, 2015 Ryan C. Hedgepeth, MD, MS Chief of
Brian Louis Cohen, M.D., M.P.H.
Brian Louis Cohen, M.D., M.P.H. MEDICAL TRAINING Fellowship in Female Urology, Voiding Dysfunction, and Reconstructive Urology Anticipated, July 2007 June 2008 Residency in Urology, July 2003 June 2007
da Vinci Prostatectomy Information Guide (Robotically-Assisted Radical Prostatectomy)
da Vinci Prostatectomy Information Guide (Robotically-Assisted Radical Prostatectomy) Prostate Cancer Overview Prostate cancer is a disease in which malignant (cancer) cells form in the tissues of the
CYBERKNIFE RADIOSURGERY FOR EARLY PROSTATE CANCER Rationale and Results. Alan Katz MD JD Flushing, NY USA
CYBERKNIFE RADIOSURGERY FOR EARLY PROSTATE CANCER Rationale and Results Alan Katz MD JD Flushing, NY USA Prostate Ablative Therapy Over the last 10 years our therapy has improved bned rates for LDR/HDR
Breast Cancer Pathway
Breast Cancer Pathway Risk Stratified Follow Up Dr Dorothy Goddard, Associate Medical Director for Cancer Macmillan Consultant Medical Advisor Survivorship What is risk stratified follow up? Refers to
Treating Prostate Cancer
Treating Prostate Cancer A Guide for Men With Localized Prostate Cancer Most men have time to learn about all the options for treating their prostate cancer. You have time to talk with your family and
Prostate cancer is the second most
Treatment Options for Localized Prostate Cancer RAVINDER MOHAN, MD, PhD, and PAUL F. SCHELLHAMMER, MD Eastern Virginia Medical School, Norfolk, Virginia In the United States, more than 90 percent of prostate
Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical
Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent
Advances in Diagnostic and Molecular Testing in Prostate Cancer
Advances in Diagnostic and Molecular Testing in Prostate Cancer Ashley E. Ross MD PhD Assistant Professor Urology, Oncology, Pathology Johns Hopkins School of Medicine September 24, 2015 1 Disclosures
Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases
I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University
The PSA Controversy: Defining It, Discussing It, and Coping With It
The PSA Controversy: Defining It, Discussing It, and Coping With It 11 TH ANNUAL SYMPOSIUM ON MEN S HEALTH June 12, 2013 The PSA Controversy Defining It, Discussing It and Coping With It As of May 2012,
Prostate Cancer 2014
Prostate Cancer 2014 Eric A. Klein, M.D. Chairman Glickman Urological and Kidney Institute Professor of Surgery Cleveland Clinic Lerner College of Medicine Incidence rates, US Men Mortality Rates, US Men
Neoadjuvant and Adjuvant Hormone Therapy: How and When?
european urology supplements 7 (2008) 747 751 available at www.sciencedirect.com journal homepage: www.europeanurology.com Neoadjuvant and Adjuvant Hormone Therapy: How and When? Hein Van Poppel * Department
CMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014
Background CMScript Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014 Prostate cancer is second only to lung cancer as the leading cause of cancer-related deaths in men. It is
2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER
2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER Humboldt County is located on the Redwood Coast of Northern California. U.S census data for 2010 reports county population at 134,623, an increase of
Oncology Annual Report: Prostate Cancer 2005 Update By: John Konefal, MD, Radiation Oncology
Oncology Annual Report: Prostate Cancer 25 Update By: John Konefal, MD, Radiation Oncology Prostate cancer is the most common cancer in men, with 232,9 new cases projected to be diagnosed in the U.S. in
ICHOM-INTERN L CONSORTIUM ON HEALTH OUTCOMES MEASUREMENT
Poster Session HRT11420 Innovation Awards November 2014 Melbourne ICHOM-INTERN L CONSORTIUM ON HEALTH OUTCOMES MEASUREMENT Jeremy Millar AlfredHealth Monash University The Health Roundtable Key problem:
PSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.
PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition [email protected] September 23, 2010 Screening: 3 tests for PCa A good screening
Re irradiation Using HDR Interstitial Brachytherapy for Locally Recurrent. Disclosure
Re irradiation Using HDR Interstitial Brachytherapy for Locally Recurrent Cervical lcancer Yasuo Yoshioka, MD Department of Radiation Oncology Osaka University Graduate School of Medicine Osaka, Japan
Prostate Cancer Screening in Taiwan: a must
Prostate Cancer Screening in Taiwan: a must 吳 俊 德 基 隆 長 庚 醫 院 台 灣 醫 學 會 105 th What is the PSA test? The blood level of PSA is often elevated in men with prostate cancer, and the PSA test was originally
Clinical Trials and Radiation Treatment. Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto
Clinical Trials and Radiation Treatment Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto What I will cover.. A little about radiation treatment The clinical trials
The Science behind Proton Beam Therapy
The Science behind Proton Beam Therapy Anthony Zietman MD Shipley Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School Principles underlying Radiotherapy Radiation related
American Urological Association (AUA) Guideline
1 (AUA) Guideline Approved by the AUA Board of Directors April 2013 Authors disclosure of potential conflicts of interest and author/staff contributions appear at the end of the article. 2013 by the American
Bridging Techniques. What s between EMR and Traditional Surgery? Elisabeth C. McLemore, MD, FACS, FASCRS
Bridging Techniques What s between EMR and Traditional Surgery? Elisabeth C. McLemore, MD, FACS, FASCRS Associate Professor of Surgery Assistant Program Director, General Surgery Residency Disclosures
Understanding the. Controversies of. testosterone replacement. therapy in hypogonadal men with prostate cancer. controversies surrounding
Controversies of testosterone replacement therapy in hypogonadal men with prostate cancer Samuel Deem, DO CULTURA CREATIVE (RF) / ALAMY Understanding the controversies surrounding testosterone replacement
Clinical Practice Assessment Robotic surgery
Clinical Practice Assessment Robotic surgery Background: Surgery is by nature invasive. Efforts have been made over time to reduce complications and the trauma inherently associated with surgery through
Recovery of Erectile Function After Radical Prostatectomy Vanderbilt University Department of Urologic Surgery
Recovery of Erectile Function After Radical Prostatectomy Vanderbilt University Department of Urologic Surgery Postoperative erectile dysfunction is a potential risk of surgery for prostate cancer, whether
Prostate Cancer. Treatments as unique as you are
Prostate Cancer Treatments as unique as you are UCLA Prostate Cancer Program Prostate cancer is the second most common cancer among men. The UCLA Prostate Cancer Program brings together the elements essential
Prostate Cancer. There is no known association with an enlarged prostate or benign prostatic hyperplasia (BPH).
Prostate Cancer Definition Prostate cancer is cancer that starts in the prostate gland. The prostate is a small, walnut-sized structure that makes up part of a man's reproductive system. It wraps around
FAQ About Prostate Cancer Treatment and SpaceOAR System
FAQ About Prostate Cancer Treatment and SpaceOAR System P. 4 Prostate Cancer Background SpaceOAR Frequently Asked Questions (FAQ) 1. What is prostate cancer? The vast majority of prostate cancers develop
Pancreatic Cancer: FDA Approved Treatments and Clinical Trials
Pancreatic Cancer: FDA Approved Treatments and Clinical Trials Vincent J Picozzi MD MMM Virginia Mason Medical Center Seattle WA 1 Pancreatic cancer is the hardest cancer of all to treat 2 Pancreatic cancer:
PATIENT GUIDE. Localized Prostate Cancer
PATIENT GUIDE Localized Prostate Cancer The prostate* is part of the male reproductive system. It is about the same size as a walnut and weighs about an ounce. As pictured in Figure 1, the prostate is
Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer
Sexual Medicine Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer Felipe G. Balbontin, Sergio A. Moreno, Enrique Bley*, Rodrigo Chacon*,
Focus on PSA Screening for Prostate Cancer Vol. 28 Supplement, February 2012. Prostate Cancer: Should We Be Screening?
Focus on PSA Screening for Prostate Cancer Vol. 28 Supplement, February 2012 Prostate Cancer: Should We Be Screening? INSIDE THIS ISSUE 2 Why the Controversy? 3 Active Surveillance 4 The Radical Prostatectomy
PSA screening in asymptomatic men the debate continues www.bpac.org.nz keyword: psa
PSA screening in asymptomatic men the debate continues www.bpac.org.nz keyword: psa Key messages: PSA is present in the benign and malignant prostate There is currently no national screening programme
Treatment and Surveillance of Non- Muscle Invasive Bladder Cancer
Treatment and Surveillance of Non- Muscle Invasive Bladder Cancer David Josephson, MD FACS Fellowship Director, Urologic Oncology and Robotic Surgery Program Staging Most important in risk assessment and
